Corcept Therapeutics, Inc. (NASDAQ:CORT)

Teknowizz (98.22) Submitted: 2/3/2012 2:29:45 PM : Start Price: $3.40 CORT Score: -18.08

PUDFA for Korlym for Cushings on Feb 17th. Given that the FDA has indicated that no REMS program is required (Risk Evaluation and Mitigation Strategy) one may expect approval.
Altough a very rare disease, CORT can use the money, so expecting a pop when approved.

Shankapotamus (< 20) Submitted: 2/2/2012 3:22:41 PM : Start Price: $3.28 CORT Score: -15.08

FDA catalyst play

bassettt (67.16) Submitted: 7/1/2011 11:44:33 PM : Start Price: $3.92 CORT Score: +29.33

This stock may be a worth less than 50 cents in a year. The drug the FDA is currently reviewing, Corlux, has the same active ingredient as the pill that is taken to eliminate early pregnancy. I don't see the FDA allowing such a drug to be distributed when Corlux would only benefit about 5-10 thousand people anyway. The rest of their pipeline is dependent on the same active ingredient.

Fiskhus (77.99) Submitted: 2/4/2011 8:21:30 PM : Start Price: $4.15 CORT Score: -35.10

MB7 Z3

NoDoughBro (70.21) Submitted: 10/21/2009 11:39:43 PM : Start Price: $2.33 CORT Score: -7.35

Gimme drugs...gimme drugs.

tiobueno (99.38) Submitted: 4/4/2008 12:29:13 PM : Start Price: $3.56 CORT Score: -23.03

March 27, 2008 12:44 PM EDT

Corcept Therapeutics Inc. (Nasdaq: CORT) Director, Joseph Cook, bought 176,522 on 3/25 at $2.77, bringing his stake to 1,656,360 shares. In addition, Director, David Mahoney, bought 70,609 shares on 3/25 at $2.77, bringing his stake to 636,547 shares.

Corcept Therapeutics Incorporated develops drugs for the treatment of severe psychiatric and metabolic diseases. [LJ]

Ajiday (20.92) Submitted: 4/4/2008 7:30:22 AM : Start Price: $3.80 CORT Score: -29.10

Health, health, health! One cannot go wrong with health. And the more they specialize and branch out, the better the prospects for these companies.

elwood713 (< 20) Submitted: 4/2/2008 3:59:18 PM : Start Price: $3.79 CORT Score: -28.39

Since the inception of this stock, given it's highs and lows, the trend shows the stock outperforming the S&P 500.